Details of Drug Interaction | MecDDI

Drug General Information (ID: DDIZX7MY6U)
Drug Name			Terazosin		Drug Info		Empagliflozin		Drug Info
Drug Type		Small molecule				Small molecule
Therapeutic Class		Antineoplastics				Antidiabetic Agents
Structure

Mechanism of Terazosin-Empagliflozin Interaction (Severity Level: Moderate)
Additive hypotensive effects Click to Show/Hide Mechanism Graph

Drug Name		Terazosin				Empagliflozin
Mechanism 1		Antihypertensive agent Alpha-1 adrenergic receptor Antagonist				Antihypertensive agent
Key Mechanism Factor 1
		Factor Name		Adrenergic receptor alpha-1				Structure Sequence
		Protein Family		G-protein coupled receptor 1 family
		Protein Function		This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) proteins. Nuclear ADRA1A-ADRA1B heterooligomers regulate phenylephrine(PE)-stimulated ERK signaling in cardiac myocytes. Click to Show/Hide
Mechanism Description		Additive hypotensive effects by the combination of Terazosin and Empagliflozin
Mechanism 2		Antihypertensive agent Alpha-1 adrenergic receptor Antagonist				Hypotensive effects
Key Mechanism Factor 2
		Factor Name		Adrenergic receptor alpha-1				Structure Sequence
		Protein Family		G-protein coupled receptor 1 family
		Protein Function		This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) proteins. Nuclear ADRA1A-ADRA1B heterooligomers regulate phenylephrine(PE)-stimulated ERK signaling in cardiac myocytes. Click to Show/Hide
Mechanism Description		Additive hypotensive effects by the combination of Terazosin and Empagliflozin

Recommended Action
Management		Caution is advised if SGLT-2 inhibitors are coadministered with diuretics and other hypotensive agents, particularly in the elderly and patients with impaired renal function. Prior to initiating SGLT-2 inhibitors, volume status should be assessed and corrected, if necessary. Clinical and laboratory monitoring are recommended during therapy, including electrolytes, fluid status, renal function, and blood pressure. If volume depletion occurs, treatment with SGLT-2 inhibitors should be interrupted until the condition is corrected.

References
1	Cerner Multum, Inc. "Australian Product Information.".
2	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
3	Product Information. Jardiance (empagliflozin). Boehringer Ingelheim, Ridgefield, CT.